Bisulfite-free, base-resolution identification of cytosine modifications

US11306355B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11306355-B2
Application numberUS-202117201825-A
CountryUS
Kind codeB2
Filing dateMar 15, 2021
Priority dateJan 8, 2018
Publication dateApr 19, 2022
Grant dateApr 19, 2022

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for identifying 5-methylcytosine (5mC) or 5-hydroxymethylcytosine (5hmC) in a target nucleic acid comprising the steps of: providing a nucleic acid sample comprising the target nucleic acid; modifying the target nucleic acid comprising the steps of: converting the 5mC and 5hmC in the nucleic acid sample to 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC) by contacting the nucleic acid sample with a ten-eleven translocation (TET) enzyme so that one or more 5caC or 5fC residues are generated; and converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the target nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified target nucleic acid; and detecting the sequence of the modified target nucleic acid; wherein a cytosine (C) to thymine (T) transition or a cytosine (C) to DHU transition in the sequence of the modified target nucleic acid compared to the target nucleic acid provides the location of either a 5mC or 5hmC in the target nucleic acid. 2. The method of claim 1 , wherein the borane reducing agent is 2-picoline borane. 3. The method of claim 1 , wherein the step of detecting the sequence of the modified target nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis. 4. The method of claim 1 , wherein the TET enzyme is selected from the group consisting of human TET1, TET2, and TET3; murine Tet1, Tet2, and Tet3; Naegleria TET (NgTET); and Coprinopsis cinerea (CcTET). 5. The method of claim 1 , further comprising a step of blocking one or more modified cytosines. 6. The method of claim 5 , wherein the step of blocking comprises adding a sugar to a 5hmC. 7. The method of claim 1 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences. 8. A method for chemically modifying a nucleic acid sample comprising the steps of: providing a nucleic acid sample comprising 5-carboxylcytosine (5caC) and/or 5-formylcytosine (5fC); and converting the 5caC and/or 5fC to dihydrouracil (DHU) by treating the nucleic acid with a borane reducing agent to provide a modified nucleic acid sample comprising a modified nucleic acid. 9. The method of claim 8 , wherein the borane reducing agent is selected from the group consisting of 2-picoline borane (pic-BH3), borane, sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride. 10. The method of claim 8 , wherein the borane reducing agent is 2-picoline borane. 11. The method of claim 8 , further comprising the step of detecting the sequence of the modified nucleic acid. 12. The method of claim 11 , wherein the step of detecting the sequence of the modified nucleic acid comprises one or more of chain termination sequencing, microarray, high-throughput sequencing, and restriction enzyme analysis. 13. The method of claim 11 , wherein the sequencing step provides a quantitative level of one or more cytosine modifications in the nucleic acid sample. 14. The method of claim 8 , wherein the method further comprises a step of amplifying the copy number of one or more nucleic acid sequences.

Assignees

Inventors

Classifications

  • DNA beta-glucosyltransferase (2.4.1.27) · CPC title

  • DNA alpha-glucosyltransferase (2.4.1.26) · CPC title

  • Methylation markers · CPC title

  • Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

  • Nucleic acid amplification reactions · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11306355B2 cover?
This disclosure provides methods for bisulfite-free identification in a nucleic acid sequence of the locations of 5-methylcytosine, 5-hydroxymethylcytosine, 5-carboxylcytosine and 5-formylcytosine.
Who is the assignee on this patent?
Ludwig Inst For Cancer Res Ltd
What technology area does this patent fall under?
Primary CPC classification C12Q1/6827. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).